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ABSTRACT 
 
Diabetes Mellitus (DM) and Osteoporosis (OP) frequently co-exist with advanced age and 
imply large health challenges worldwide. The last decades there has been a growing interest 
regarding fracture risk in DM. Currently used screening methods (Dual Energy X-ray 
Absorptiometry (DXA) and FRAX) underestimate fracture risk in diabetes patients. New 
methods for risk assessment are needed. In my thesis, we have studied the significance of 
neuropathy, the IGF-system and metabolic control in relation to bone mineral density and 
fracture risk in DM, both in a rat-model and in humans.  
Study I: In an epidemiological register study of 24 605 patients, 12 551 men and 12054 
women with T1DM the cumulative incidence of hip fractures was analyzed. Conclusion: 
Both men and women with TIDM have a several folds increased risk for hip fracture with 
higher risk in those with peripheral neuropathy.  
Study II: Diabetic osteopathy and the IGF-system were analyzed in an animal model of mild 
T2DM, the Goto-Kakizaki rat, to assess the systemic as well as local bone and joint status. 
Conclusion: Bone mineral density (BMD) was lower in peripheral bone in diabetic compared 
to control rats and there were both systemic and local disturbances of the IGF-system  
Study III: Bone and joint neuropathy were studied in the same diabetic rats and compared to 
controls to explore and define abnormalities of the peripheral nervous system in diabetic 
osteopathy according to nerve conduction velocity and neuropeptide expression in bone and 
joints. Conclusion: Rats with mild T2DM and neuropathy exhibited neuropeptidergic changes 
in the periphery, especially autonomic nerve deficits, which we suggest is an important factor 
underlying the development of regional osteopenia.   
Study IV: In a prospective clinical study 66 subjects with T1DM or T2DM with peripheral 
poly-neuropathy (PNP) were followed for a mean of 11 years in T1DM and 8 years in T2DM 
to investigate fracture incidence and risk factors. Quantitative ultrasound (QUS) of calcaneus 
but not DXA spine or femur neck predicted future fractures. Fracture incidence was high in 
this cohort of poorly controlled diabetes subjects with the mean age of 58 years at inclusion. 
DXA spine T score was normal in both T1DM and T2DM, while T score DXA femoral neck 
and QUS of calcaneus were low, which correlated well. QUS of calcaneus and low levels 
IGFBP-5 predicted future fracture of the hip and foot. There was an inverse correlation 
between the incidence of any fracture and baseline levels of serum IGF-I. There were no 
gender differences or difference between type of diabetes in the incidence of fractures or risk 
factors. 
In summary, the results of our studies show that peripheral local osteopenia occurs in diabetes 
associated with impaired IGF availability/activity and PNP independent of type of diabetes or 
gender and leads to an increased incidence of peripheral fractures. The pathogenesis behind 
fractures in DM is multifactorial. Neuropathy, microangiopathy and metabolic factors 
including the IGF system influence the development of peripheral osteopenia and fracture 
risk. This indicates that assessment of fracture risk should be follow in diabetes patients 
besides microangiopathy and neuropathy. QUS of calcaneus, serum levels of IGF-I and 
IGFBP-5 could be complementary screening methods for fracture risk assessment in subjects 
with diabetes and PNP.   
  
 
 
  
  
LIST OF SCIENTIFIC PAPERS 
I. Miao J, Brismar K, Nyrèn O, Ugarph-Morawski A, Ye W: Elevated hip 
fracture risk in type 1 diabetic patients: a population based cohort study in 
Sweden. Diabetes Care. 2005 Dec;28(12):2850-2855. 
II. Ahmad T, Ugarph-Morawski A, Lewitt MS, Li J, Sääf M, Brismar K. 
Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat. Growth 
Horm IGF Res. 2008 Oct;18(5):404-411. 
III. Ahamad T, Ugarph-Morawski A, Li J, Bileviciute-Ljungar I, Finn A, 
Östenson CG, Kreicbergs A. Bone and joint neuropathy in rats with type-2 
diabetes. Regul Pept. 2004 Jun 15;119(1-2):61-67. 
IV. Ugarph-Morawski, Sääf M, Brismar K. Predictors of fractures and bone 
disease in subjects with Diabetes Mellitus and Peripheral Neuropathy. 
Manuscript. 
  
INNEHÅLLSFÖRTECKNING 
1 Introduction ..................................................................................................................... 1 
2 Hypothesis and Aims ...................................................................................................... 5 
3 Material and Methods ..................................................................................................... 7 
3.1 STUDY I ................................................................................................................ 7 
3.1.1 Ethics ......................................................................................................... 7 
3.1.2 Registers .................................................................................................... 7 
3.1.3 The Type 1 Diabetes Mellitus Cohort ...................................................... 8 
3.1.4 Follow Up .................................................................................................. 8 
3.1.5 Statistical Analyses ................................................................................... 8 
3.2 STUDY II AND III: Animal model, anesthesia and euthanasia .......................... 9 
3.2.1 Ethics ......................................................................................................... 9 
3.2.2 Animal Model ........................................................................................... 9 
3.2.3 Glucose Tolerance Test ............................................................................. 9 
3.2.4 Radiography ............................................................................................ 10 
3.2.5 Dual Energy X-Ray Absorptiometry ...................................................... 10 
3.2.6 Radioimmunoassays ............................................................................... 10 
3.2.7 Statistical Analyses ................................................................................. 10 
3.3 STUDY IV ........................................................................................................... 11 
3.3.1 Ethics ....................................................................................................... 11 
3.3.2 The Type 1 And Type 2 Diabetes Mellitus Cohort ................................ 11 
3.3.3 Peripheral Circulation ............................................................................. 11 
3.3.4 Peripheral Neuropathy ............................................................................ 11 
3.3.5 Nephropathy ............................................................................................ 12 
3.3.6 Quantitative Ultrasound Of Calcaneus ................................................... 12 
3.3.7 Dual Energy X-Ray Absorptiometry ...................................................... 12 
3.3.8 Radioimmunoassays ............................................................................... 12 
3.3.9 Medical Records And Registers ............................................................. 13 
3.3.10 Statistical Analyses ................................................................................. 13 
4 Results ........................................................................................................................... 15 
4.1 STUDY I .............................................................................................................. 15 
4.1.1 Incident Hip Fracture In Patients With Type 1 Diabetes Mellitus ........ 15 
4.1.2 Cumulative Risk Of Hip Fracture In Patients With Type 1 
Diabetes Mellitus .................................................................................... 15 
4.2 STUDY II ............................................................................................................ 16 
4.2.1 Diabetes ................................................................................................... 16 
4.2.2 Radiography ............................................................................................ 16 
4.2.3 Dual Energy X-Ray Absorptiometry ...................................................... 16 
4.2.4 The IGF System And Insulin .................................................................. 16 
4.3 STUDY III ........................................................................................................... 17 
4.4 STUDY IV ........................................................................................................... 18 
4.4.1 Study Subjects ......................................................................................... 18 
4.4.2 Quantitative Ultrasound And Dual Energy X-Ray Absorptiometry 
(Table 2b) ................................................................................................ 21 
4.4.3 Follow Up Events .................................................................................... 22 
  
5 Discussion ...................................................................................................................... 25 
5.1 Fracture Incidence: .............................................................................................. 25 
5.2 Metabolic Factors ................................................................................................ 26 
5.2.1 Body Mass Index (BMI) ......................................................................... 26 
5.2.2 Hba1c ....................................................................................................... 26 
5.2.3 The IGF System ...................................................................................... 26 
5.2.4 Peripheral Neuropathy ............................................................................ 27 
5.2.5 Bone Parameters ...................................................................................... 28 
6 Conclusions ................................................................................................................... 29 
7 Future Perspectives........................................................................................................ 30 
8 Acknowledgements ....................................................................................................... 31 
9 References ..................................................................................................................... 33 
 
  
  
LIST OF ABBREVIATIONS 
BMD 
BMC 
BMI 
BP 
BUA 
CGRP 
CI 
DM 
DXA 
HbA1c 
IGF 
IGFBP 
i.p 
NCV 
NPY 
PNP 
QUS 
RIA 
SHR 
SOS 
SP  
WHO 
Bone Mineral Density 
Bone Mineral Content 
Body Mass Index 
Blood Pressure 
Broad Band Attenuation 
Calcitonin Gene Related Peptide 
Confidence Interval 
Diabetes Mellitus 
Dual Energy X-Ray Absorptiometry 
Glycated hemoglobin 
Insulin-like Growth Factor 
Insulin-like Growth Factor Binding Protein 
Intraperitoneal injection 
Nerve Conduction Velocity 
Neuropeptide Y 
Peripheral Neuropathy 
Quantitative Ultra Sound 
Radioimmunoassay 
Standardized Hospitalization Ratios 
Speed of Sound 
Substance P 
World Health Organisation 
 
  1 
1 INTRODUCTION 
The incidence of Diabetes Mellitus (DM) is increasing worldwide, most significantly type 2 DM 
(T2DM) but also type 1 DM (T1DM). (1-2) In 2013, 382 million people had DM. By 2035 this 
number is expected to rise to 592 million people. (3) T1DM affects 5-10% and T2DM 80-85% of the 
DM population. T1DM is characterized by absolute insulin deficiency due to beta cell dysfunction 
and has an autoimmune etiology. T2DM is characterized by deficiency in insulin secretion and 
insulin resistance. The dramatic increase in the prevalence of T2DM substantially depends on 
changes in lifestyle due to urbanization. Diabetes Mellitus is associated with several complications 
and comorbidities. The increased incidence of DM will impose a substantial burden on the health 
care system. To encounter this growing epidemic there is a need to appropriately allocate resources, 
identify individuals at risk of developing DM as well as individuals with manifest DM, to 
implement preventive measures of late complications. Until recently bone disease has not been 
included in the list of DM complications.  
 
Osteoporosis (OP) is another public disease affecting millions of people worldwide. OP is defined 
as “a disease that is characterized by low bone mass, microarchitectural deterioration of bone tissue 
leading to enhanced bone fragility, and consequent increase in fracture risk”. (4) OP is a silent 
disease until a fracture occurs, why primary prevention is problematic. OP often remains 
underdiagnosed and undertreated. Accordingly, secondary prevention is the most common approach 
for fracture prevention.  
The presence of OP related to DM has been less acknowledged and it´s clinical relevance less 
obvious than that of other DM complications. However, there is a growing awareness that T1DM 
and T2DM both predispose to bone fracture. (5) The lifetime risk of an osteoporotic fracture in the 
general population in Rochester, Minnesota, has been estimated to almost 40% in white women and 
13% in men from the age of 50 years onward. (6) However, a Swedish study reported substantially 
higher fracture incidence in an age- and sex standardized material. (7) A higher incidence is found in 
northern compared to southern Europe with differences in the epidemiologic pattern of hip fracture. 
(8) In subjects with T1DM there is an about six-fold increase in hip fracture risk and an about 
twofold increase in vertebral fracture risk compared to non-diabetic individuals. (9) T2DM is 
associated with an about two- to threefold increase in hip fracture risk compared with non-diabetic 
individuals, despite normal or high BMD. (10) In the ageing population, the likelihood to develop 
DM and/or OP are both increased.  
According to current guidelines Dual Energy X-ray Absorptiometry (DXA) and Fracture Risk 
Assessment Tool (FRAX) are used to give information on the likelihood of future fractures. 
Previous reports demonstrate that those with T1DM generally have decreased Bone Mineral 
Density (BMD) measured by DXA and subsequent increased risk for osteopenia and osteoporosis, 
notably in the feet and femoral neck, being a risk for future fractures and Charcot Neuroarthropathy 
(CN) resulting in additional morbidity and mortality. (11) Lately several reports have found that 
T2DM as well implies an independent risk factor for fracture. (12) Compared to control subjects, 
decreased BMD has been observed in T1DM, while contradictory results with higher, lower or 
normal values for BMD have been reported in T2DM patients. (13-16) In the non-diabetic population 
high BMD is considered a protective factor against fracture. However, in T2DM the association 
between BMD and fracture risk seems different, since T2DM patients have been reported to have 
higher risk of fracture despite normal or high BMD. (13) Previous studies have shown that the World 
Health Organization’s (WHO) FRAX calculator underestimates fracture risk in individuals with 
T2DM. (17) Consequently, it is problematic to assess bone fragility in T2DM subjects by 
conventional methods. Bone strength includes several features: bone mineral density, bone 
structure, geometry, cortical architecture, trabecular architecture and bone turnover. DXA provides 
an estimation of bone density but does not capture other bone quality factors. Besides BMD, 
complications of DM (peripheral neuropathy (PNP), nephropathy, retinopathy), propensity to fall, 
hypoglycemia and decreased bone material properties influence fracture risk. (18-20)  
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The underlying mechanisms for increased fracture risk in patients with DM are indeed complex, 
multifactorial and are not fully established. Furthermore, T1DM and T2DM are heterogeneous 
diseases whose pathophysiological background and bone phenotype differ considerably.  
A selection of factors affecting bone metabolic status in DM will follow.  
 
Metabolic control 
 
There is evidence that glycemic control is associated with bone health. Poor glycemic control seems 
to be associated with increased fracture risk in both T1DM and T2DM subjects. (21) Chronic 
hyperglycemia has effects on both cellular and extracellular bone matrix, leading to impairment of 
osteoblast function. (22-23) In addition, high p-glucose generates the formation of advanced glycation 
end products (AGE). AGEs may play a potential role in the development of skeletal abnormalities 
by deteriorating bone quality and material properties, increasing stiffness and brittleness in bone. (24) 
Bone consists of a collagen network (90%) that is susceptible to a variety of molecular alterations. 
Because of hyperglycemia, normal enzymatic crosslinking in collagen is decreased and AGE 
crosslinking increased, leading to more brittle bones that are less able to deform before fracturing. 
(25) AGEs modify the organic bone material but not the mineral content in bone and can thus not be 
assessed by DXA. Accordingly, longer duration of the disease and worsened glucose control are 
associated with higher risk of fractures.  
 
Insulin-like growth factor system 
Insulin-like growth factor-I 
    
Bone remodeling is regulated by systemic hormones and locally produced factors interacting to 
maintain bone mass. (26) IGF-I is regarded as a key regulator of bone metabolism, both in skeletal 
growth and remodeling, in response to growth hormone (GH) exposure.  GH may act directly on 
bone cells but most of its effects are mediated by IGF-I in both cortical and trabecular bone. In the 
adult skeleton, bone resorption and formation are coupled to maintain bone mass. Bone remodeling 
in the adult skeleton is necessary to remove potentially damaged bone. GH from the pituitary, 
parathyroid hormone (PTH) and insulin stimulates the production of IGF-I. (27) IGF-I is a hormone 
with similar molecular structure to insulin and has important functions in regulating cell growth, 
differentiation and metabolism.  It has glucose lowering and insulin sensitizing effects which is 
beneficial for glucose homeostasis. It exerts it´s actions by binding to the insulin-like growth-factor-
I-receptor (IGFIR) and the insulin receptor on the cell surface. These receptors are present in most 
tissues, including bone. IGF-I is primarily produced by the liver acting as an endocrine hormone, 
but is also produced by other tissues acting in a paracrine/autocrine manner. (100) In bone tissue IGF-
I is synthesized in osteoblasts promoting proliferation and differentiation of osteoblasts, 
chondrocytes and collagen synthesis. The production of IGF-I is decreased in conditions of insulin 
deficiency and malnutrition.  Diseases affecting the IGF system are associated with significant 
alterations in bone metabolism leading to decreased bone mass. (28) IGF-I is biologically active only 
in unbound form and its action is modulated by a family of six binding proteins (IGFBP) with 
different functions. IGFBPs bind to IGF-I with an affinity equal to or greater than that of the IGF-I-
receptor. When present in excess, tissue IBFBPs inhibit IGF actions by forming biologically 
inactive complexes that cannot bind to the IGF-I-receptors. The precise function of each IGFBP is 
still insufficiently understood, but they function as a storage pool of IGF-I, inhibit the action of 
IGF-I or potentiate the action of IGF-I. In this thesis, the focus will be on IGFBP-1, -4 and -5.  
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Insulin-like growth-factor binding protein-1 (IGFBP-1) 
 
Phosphorylated IGFBP-1, produced mainly in the liver, inhibits IGF-I anabolic effects and 
influences the metabolic and mitogenic effects of IGF-I. (29, 101) Insulin inhibits the hepatic synthesis 
of IGFBP-1. (30) High levels of IGFBP-1 has been associated to low BMD. (31) Conversely, IGFBP-1 
is elevated in insulin deficiency, catabolic states and kidney failure.  
 
Insulin-like growth-factor binding protein-3 (IGFBP-3) 
 
IGFBP-3 is the major carrier of IGF-I in the circulation and is mostly regulated by GH and/or IGF-
I1. There are reports suggesting that patients with vertebral fractures have significantly lower levels 
of IGF-I and IGFBP-3 than controls without fractures. (32)  
 
Insulin-like growth factor binding protein-4 (IGFBP-4) 
 
IGFBP-4 is produced by the liver and in other tissues. In bone, it is produced by osteoblasts and is 
generally believed to inhibit the actions of IGF-I in bone cells by binding to the IGF-I receptor. (33)  
 
Insulin-like growth factor binding protein-5 (IGFBP-5) 
 
IGFBP-5 is the most abundant IGFBP in bone tissue secreted by osteoblasts and potentiates IGF-1 
stimulated DNA- and protein synthesis in osteoblasts, chondrocytes, fibroblasts and smooth muscle 
cells. IGFBP-5 may also function as a growth factor by stimulating osteoblasts via an IGF-I 
independent mechanism. (34-36) 
  
Neuropathy  
 
Diabetic peripheral polyneuropathy (PNP) is the most frequent neuropathy in western countries. 
Peripheral nerve function deteriorates with age in the general population, but more rapidly in 
patients with diabetes. (37) PNP affects both sensory and autonomic neurons. Previous reports 
indicate that the autonomic nervous system is more susceptible to hyperglycemia and is therefore 
affected first in DM patients. (37) The condition is related to duration of diabetes, metabolic control 
and occurrence of microvascular complications. There are several reports that indicate an important 
role of sensory and sympathetic nerve fibers in regulating bone remodeling. (38) Neuropeptides from 
sensory and sympathetic nerve fibers in the periphery are involved in the regulation of bone 
metabolism. (39)  
The autonomic neuropathy causes an increased blood flow, due to the development of arteriovenous 
shunts, contributing to increased bone resorption, osteopenia and bone fragility with subsequent 
fractures as consequence. Sensory neuropathy leads to loss of protective sensory capacity in bone 
and joints causing abnormal stress on the foot, imbalance in muscle, tendons and joints. Due to 
sensory deficit, repetitive trauma with micro-fractures and joint dislocations can initially pass 
undiscovered. These events contribute to the development of Charcot Neuroarthropathy (CN). CN 
also involves a local inflammatory process, gradual development of bone loss and permanent 
deformities of the foot skeleton. (40-41) Additionally, sensory deficit causes instability and increased 
fall frequency with increased risk of any fracture.  
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In summary PNP, besides increased fall frequency, may affect bone through abnormal 
vasoregulation, but probably has direct effects on bone as well. Interactions between neuropeptides 
and growth factors as well as cytokines indirectly effect bone metabolism. The exact influence of 
the nervous system in bone maintenance is still unclear and further studies are required. 
Neuropeptides  
 
Substance P (SP) 
 
SP is a neuropeptide acting as a neurotransmitter and as a neuromodulator. It is an important 
element in pain perception transmitting pain information from sensory nerves to the central nervous 
system. SP is released from sensory nerve fiber terminals and from inflammatory cells 
(macrophages, eosinophils, lymphocytes and dendritic cells). It is also found in the spinal cord 
(dorsal root ganglia) and in the brain. In addition, SP plays an important role in the inflammatory 
and angiogenetic phases of wound healing. Previous reports suggest that SP in the peripheral 
nervous system (PNS) contributes to maintain bone integrity, regulation of bone formation and 
resorption. (42)  
Calcitonin Gene Related Peptide (CGRP) 
 
CGRP is produced in nerves both in PNS and CNS, including skeletal nerve fibers in the periosteum 
and bone marrow. It is a potent vasodilator and is thought to control local blood flow. CGRP is 
derived mainly from sensory nerves, but also has autonomic functions. It mediates its effects on 
receptors found throughout the body including bone tissue. There are previous reports that CGRP is 
associated with bone formation. (43) It also stimulates osteoblast proliferation, synthesis of growth 
factors (including IGF-1), cytokines, collagen and bone formation in vivo. (44-46)  
 
Neuropeptide Y (NPY) 
 
NPY is one of the most abundant neurotransmitters in the brain and the autonomic nervous system 
of humans. It has vasoconstrictive and mitogenic effect on blood vessels and seems to be involved 
in blood pressure regulation and angiogenesis. Previous reports provide evidence that NPY fibers 
are present in bone, most commonly associated to blood vessels which indicate that NPY also has 
vaso-regulatory effects in bone. (47) In the PNS, NPY appears to have pro-osteogenic effects. (48) 
NPY is co-released with noradrenaline from sympathetic nerves. Sympathectomy has been shown 
to increase osteoclast number and modulate osteoblastic response to noradrenaline and PTH. (49-51) 
Thus, presumably disorders in the PNS with subsequent altered expression of neuropeptides has 
adverse effects on bone metabolism. 
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2 HYPOTHESIS AND AIMS 
Based on the hypothesis that Diabetes Mellitus type 1 (T1DM) and type 2 (T2DM) lead to 
bone tissue dysfunction including osteopathy and fracture due to metabolic disturbances and 
other DM complications, the present thesis included the following aims:  
 
Study 1: To quantify the cumulative and relative risk of hip fracture in men and women with 
T1DM. 
 
Study 2: To assess if abnormalities in the IGF-system in bone and joint may prove to underlie 
diabetic osteopathy, a study in an animal model of mild T2DM in rats was performed.  
 
Study 3: To study if bone and joints are affected by neuropathy in T2DM, Nerve Conduction 
velocity (NCV) in the sciatic nerve and neuropeptides in these tissues were investigated in an 
animal model of mild T2DM in rats.  
 
Study 4: To compare the methods Dual Energy X-Ray Absorptiometry (DXA) and 
Quantitative Ultrasound of Calcaneus (QUS) and investigate their ability to predict future 
fracture. In addition to study if bone parameters, measured by these methods, were associated 
with metabolic factors, including the IGF-system, in subjects with T1DM and T2DM and 
peripheral neuropathy (PNP).  
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3 MATERIAL AND METHODS 
 
 
 TABLE 1: SUMMARY OF STUDY DESIGN 
 
 
3.1 STUDY I 
3.1.1 ETHICS 
This study was approved by the regional ethics committee at the Karolinska Hospital.  
3.1.2 REGISTERS 
Initially 25 221 records with a discharge diagnosis of T1DM were identified in the Swedish 
Inpatient Register. These records were further linked to the Register of Total Population, the 
Register of Domestic and Foreign Migration, and the Death Register. 171 records, with 
national registration numbers that could not be found in any of the registers, were excluded. 
In addition, 376 patients with date of emigration before the index hospitalization, 43 patients 
who died on the index hospitalization and 26 patients who already had hip fractures before 
Study I
24 605 DM1 
•The Swedish Inpatient 
Register
•Register of Total 
Population
•Register of Domestic 
and Foreign Migration
•The Causes of Death 
Register
•Incidence
•ICD 10 codes (cross-
linkage within the 
Inpatient Register)
•Fracture 
•hip (femoral neck, 
pertrochanteric) 
•Rethinopathy
•Nephropathy
•Neuropathy
•Cardiovascular 
complications
Study II and III
18 GK rats + 21 Wistar 
female rats
•Glucose tolerance test 
•Neuropathy
•nerve conduction 
velocity
•Bone mineral
•DXA
•humerus
•vertebrae
•tibia
•Immunoassays
•Insullin
•IGF system serum
•IGF-1 cortilal bone and 
joint
•Neuropeptides cortical 
bone, ankle, spinal 
cord, dorsal root 
ganglia
•Immunohistichemistry
•Neuropeptides cortical 
bone, ankle, spinal 
cord, dorsal root 
ganglia
Study IV
27 DM1 + 35 DM 2
•Metabolic control
•HbA1c
•Neuropathy
•Monofilament
•Biothesiometry
•Bone Mineral
•Dual Energy X-ray 
Absorptiometry
•Quantitative Ultrasound 
Calcaneus
•Immunoassays
•IGF-1
•IGFBP-1, -4 and -5
•Incidence
•Medical records (ICD 
10 codes)
•Fracture
•Charcot
•Amputation
•The Causes of Death 
Register
•Mortality
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the index hospitalization were excluded. The final T1DM cohort included 24 605 subjects. 
(Table 1) 
With minor exceptions, in-hospital medical services in Sweden have been exclusively public, 
organized by the community. In-hospital care registrations is in practice population based and 
referred to the county were the patients live, since patients have been constrained to use the 
hospitals in their county of residence. The Swedish In-patient Register was established by the 
National Board of Health and Welfare in 1964-1965, but most counties joined the registration 
later. The Register became nationwide 1987. Each record in the register corresponds to one 
hospital admission. In addition to the patient´s national registration number (a unique 
identifier assigned to all Swedish residents), each record contains the dates of admission and 
discharge, codes for all surgical procedures and discharge diagnoses. During 1984-1986 five 
counties lacked national registration numbers for 1-2 years.  
3.1.3  THE TYPE 1 DIABETES MELLITUS COHORT  
The ICD coding before the 10th revision introduced 1997 did not allow us to separate T1DM 
from T2DM. Even after 1997 some patients coded as having T1DM had advanced T2DM 
that had developed insulin dependency. Thus, the age < 30 years at the first hospital 
admission for DM was used as an obligatory criterion. In an analysis, exclusively with 
patients hospitalized in 1998, when the ICD-10 codes were used in Sweden allowing 
differentiation between T1DM, T2DM and other DM, of 3 730 DM patients diagnosed at age 
31 or younger, 3542 had a diagnosis of insulin-dependent type of DM. Accordingly, the age 
algorithm used in the study had a positive predictive value for T1DM of 95%. The obtaining 
of cohort data began at different dates in different counties depending on when full 
registration coverage without interruption had been established. The first county included was 
1 January 1975 and the last 1 January 1989.  
3.1.4 FOLLOW UP 
The subjects in the cohort were followed from the index hospitalization for T1DM until 
occurrence of a first hospitalization for hip fracture, emigration, migration to a county 
without or with incomplete Inpatient Register coverage, death or the end of follow up (31 
December 1998), whatever occurred first. The first hospitalization for hip fracture, if any, 
was identified through cross-linkage within the Inpatient Register. Complications of diabetes 
were identified in a similar way. Vital status and coverage by the Inpatient Register was 
ascertained by linkage to the registers of Death and Domestic and Foreign Migration.  
 
3.1.5 STATISTICAL ANALYSES 
Lifetime cumulative probability of developing hip fracture before the age of 65 years was 
calculated by using the Kaplan-Meier method. Standardized Hospitalization Ratios (SHR; the 
ratio of the observed to the expected numbers of first hospitalizations for hip fractures) served 
as a measure of relative risk. The entire Inpatient Register was used to calculate the 
background hospitalization rates for the diagnoses of interest (femoral neck, per trochanteric 
and multiple site fractures) and then for any hip fracture regardless of type in the general 
population by age (5 years sub-groups), sex and calendar period (every 2 years from 1975 to 
1998). Stratum specific hospitalization rates were calculated by dividing the number of hip 
fractures by the corresponding number of general population at risk. The expected number of 
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hip fracture hospitalizations in the cohort was derived by multiplying the observed number of 
person-years in age, sex and calendar period strata by the corresponding stratum specific 
hospitalization rates. 95% confidence interval (CI) were calculated by assuming that the 
number of observed events followed a Poisson distribution. (52) We did not analyze multiple 
site hip fractures since no such case was found in our cohort.  
Additional analyses were stratified according to follow up duration. X2-test for linear trend 
was used to evaluate the time-risk relationship. (53) Presence/absence of DM complications 
was stratified. To the complication-negative strata, person-time experienced before the onset 
of complications was assigned.  
Multivariate regression analysis (Poisson regression method) was used to analyze the 
independent effects of explanatory variables.  
3.2 STUDY II AND III: ANIMAL MODEL, ANESTHESIA AND EUTHANASIA 
3.2.1 ETHICS 
The animals were cared for according to the Karolinska Institute´s protocol and had ad 
libitum access to rat chow and tap water. All animal experiments were performed with 
approval from the local Animal Research Ethics Committee. X-ray and DXA examinations 
were made under Hyponorm anesthesia. The animals were euthanized by decapitation under 
anesthesia with Hyponorm (Janssen Pharma, Beerse, Belgium, 0.5 ml/kg, i.p) and samples 
were collected and frozen for immunoassay (IGF- and neuropeptide analysis) and by 
exsanguination for immunohistochemistry (morphological analysis of nerve fiber 
distribution).  
3.2.2 ANIMAL MODEL 
18 untreated female Goto-Kakizaki rats (GK rats) aged 12 months and 21 age-matched 
control Wistar rats (B&K Universal, Stockholm Sweden) were used. The GK rat has 
previously been developed in Japan by Goto et al. through selective inbreeding of Wistar rats 
based on impaired glucose tolerance, (54) thus the latter are eminent non-diabetic controls. The 
GK rats exhibit mild to moderate hyperglycemia of spontaneous onset as soon as 1 week after 
birth, associated with normal or slightly elevated plasma insulin levels, in the fed state, and an 
impaired insulin response to glucose. With advancing age, they develop insulin deficiency 
and chronic diabetes complications (neuropathy, nephropathy and retinopathy) although the 
metabolic abnormality is not severe. (55) Furthermore, the conduction velocity of peripheral 
nerves progressively declines with age and the ultrastructural changes in nerve fibers are 
similar to those seen in human diabetic subjects with neuropathy. (56) Previous studies have 
reported the appropriateness of this animal model for the study of neuropathy and osteopathy. 
(57) An animal model was used since the intention of study I and II was to analyze IGF-I and 
neuronal mediators in bone and joint why a human model was not considered ethically 
justifiable.  
3.2.3 GLUCOSE TOLERANCE TEST  
After an overnight fast the animals were given an intraperitoneal injection of glucose solution 
(2g/kg body weight) and tail blood glucose levels were determined (fasting, 30 and 120 min 
post-injection) to assess the diabetic status of the GK-rats, using a blood glucose analyzer 
(Accutrend, Boehring Mannheim, Mannheim, Germany).  
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3.2.4 RADIOGRAPHY 
X-rays of humerus and tibia were done using a dental X-ray machine (Heliodent DS, Siemens 
AG, Bensheim, Germany) and occlusal size films (Ektaspeed Plus, Eastman Kodak, 
Rochester, NY, USA). X-rays were digitalized with a scanner (Scanjet II, Hewlett Packard, 
Singapore) and printed at 20X magnification. The outer diameter of the cortex and medullary 
canal were measured in the distal third of the diaphysis with a precision caliper. Outer 
(periosteal) diameter divided by the inner (endosteal) gave the cortical thickness index. Mean 
of measurements by two blinded observers was calculated. The correlation between the 
observers was r=0.65 and inter-observer variation was 9%. 
3.2.5 DUAL ENERGY X-RAY ABSORPTIOMETRY 
Whole body DXA was performed using a clinical DXA machine with small animal software 
(QDR 4500, Hologic, Bedford, MA, USA). The whole body and regional high-resolution 
scans for humerus and tibia (whole bone, metaphysis, diaphysis) were analyzed by defining 
windows of fixed length, i.e. tibia: metaphysis in the proximal 15% of the bone length and 
diaphysis in the distal 15%; humerus: proximal 20% and middle 15%. The inter-scan 
variation was 3%. 
3.2.6 RADIOIMMUNOASSAYS 
Radioimmunoassay’s (RIA) were done to analyze IGF-1, IGFBP-1 and IGFBP-4 in serum 
(99). Immunoassays were also done for quantification of IGF-1 and neuropeptides in tissue 
extracts. The animals were decapitated, blood was collected, centrifuged and the serum was 
frozen. Both ankles were collected, including the distal tibia and hind-foot. Vertebral bodies 
of L2-L5 vertebrae and the diaphyseal portions of both tibiae and femora were collected. 
Cortical bone was cleared of periosteum and bone marrow. Samples were immediately 
weighed and stored at -70 C. IGF-1, IGFBPs and neuropeptides were extracted from tissues 
according to the methodology previously described for neuropeptide extraction. (58-59)) Serum 
IGF-1 concentration was determined by RIA according to the methodology previously 
described by Bang et al. (60) Serum IGFBP-1 concentrations were measured using plate 
immunoassay as previously described by Povoa et al. (29, 61) IGFBP-4 was measured by RIA 
at the Laboratory of Growth and Development, California Pacific Medical Center Research 
Institute, San Francisco, USA, according to the method of Chelius et al, (62) who has reported 
serum IGFBP-4 levels in control rats from the current project. Serum insulin was measured 
using a commercial rat insulin RIA kit (Linco Research, St Charles, MO, USA). 
3.2.7 STATISTICAL ANALYSES 
Mean and standard deviation were used to summarize the measurements. In normally 
distributed data, Student´s T-test was used for comparison of means between control and 
diabetic group. In skewed variables, group comparisons were done using Mann-Whitney test, 
and correlations were performed using log-transformed data. For significance p-value < 0.05 
was chosen.  
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3.3 STUDY IV 
3.3.1 ETHICS 
This study was approved by the local ethic committee at the Karolinska Institute, Stockholm, 
Sweden, and satisfied the criteria of the World Medical Association Declaration of Helsinki – 
Ethical Principles for Medical Research Involving Human Subjects. All participants provided 
informed consent.  
3.3.2 THE TYPE 1 AND TYPE 2 DIABETES MELLITUS COHORT 
62 individuals with T1DM (n=27, 14 women, 13 men) and T2DM (n=35, 14 women, 21 
men) diagnosed with peripheral neuropathy (PNP) were included in the cohort during 1995-
1998. DM was defined as T1DM or T2DM according to American Diabetes Association, 
Classification and Diagnosis of Diabetes. (63) At inclusion diabetes duration in T1DM subjects 
were 28± 13.6 years and in T2DM 13± 9 years. In T2DM subjects, 29 (83%) were treated 
with insulin, 4 (11%) with tablets and 2 (6%) with diet regime. Obviously all T1DM subjects 
were treated with insulin. Participants were followed from the time of inclusion until the first 
incident fracture, death or end of study (December 2015) resulting in 610 person-years with a 
median follow up time of 11 years in T1DM subjects and 8 years in T2DM subjects (range 1-
20 years).  All participants were consecutively referred to a multidisciplinary foot care team 
at department of Endocrinology at the Karolinska Hospital in Stockholm, Sweden. Clinical 
assessment and interview was made at base line. Clinical assessment measures included 
weight, height, blood pressure and examination of the feet. Body mass index (BMI=kg/m2) 
was calculated based on weight and height. Hypertension was defined as blood pressure ≥ 
140/90 mmHg at examination or antihypertensive treatment. 16 individuals (7 T1DM, 9 
T2DM) had Charcot foot deformations at inclusion. The participants were asked about 
smoking habits (present and previous), physical activity (active: normal daily life activity, 
including walks; inactive: immobilized or less than 10 minutes physical activity per day), 
history of thyroid disease, gastro-intestinal disease and heredity for osteoporotic fractures. 21 
of the participants were postmenopausal (7 T1DM, 14 T2DM).  
 
3.3.3 PERIPHERAL CIRCULATION 
Examination regarding peripheral circulation was performed (pedal pulses a dorsalis pedis 
and a tibialis posterior, palpable or by Doppler). Individuals with severe macroangiopathy 
without pedal pulses (a dorsalis pedis and a tibialis posterior) and an ankle/arm index < 0.7 
were excluded. 
3.3.4 PERIPHERAL NEUROPATHY 
Peripheral sensory neuropathy was tested regarding vibration and touch. Sensibility to touch 
was detected by performing monofilament tactility test (10gram Touch Test 5.07 Novo 
Nordisk, Copenhagen, Denmark) (64) at four points at each foot. Vibration perception 
threshold using Biothesiometry (65) at the metatarsophalangeal joint dig I. Clinical signs of 
autonomic neuropathy were evaluated with presence of dry, warm, shiny skin, loss of 
perspiration and absence of hair on the foot. A standard protocol designed to assess risk of 
future foot problems was used. (66) All participants presented peripheral neuropathy, a 
majority both sensory and autonomic.  
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3.3.5 NEPHROPATHY 
Nephropathy was defined as incident micro- or macro-albuminuria (3.0-30 g albumin/mol 
creatinine and > 30 g albumin/mol creatinine respectively) measured at two separate 
occasions. Urinary albumin was analyzed at the hospital laboratory with an immunological 
method, Beckman Array (Beckman Coulter Inc, Fullerton, USA). S-Creatinine (ref for 
women > 100 and men > 110 mmol/L) was analyzed at the hospital laboratory with a 
Creatinine aminohydrolas method, VITROS instrument (Johnson & Johnson, New Jersey, 
USA). 
3.3.6 QUANTITATIVE ULTRASOUND OF CALCANEUS 
The participants underwent QUS (Lunar Achilles Bone Densitometer) assessment of 
calcaneus in both feet at baseline. Mean value of both feet were calculated. In a subgroup 
(n=46, 74%) another QUS assessment was made after approximately 3 years. Quantitative 
ultrasound (QUS) is a bone health assessment tool that does not involve exposure to 
radiation, is affordable and the devices are portable, which could increase accessibility. (67-72) 
The velocity (speed of sound=SOS, m/s) and frequency-dependent attenuation (broad band 
attenuation=BUA, dB/MHz) of the ultrasound signal is measured.  Stiffness index is 
automatically calculated from broadband ultrasound attenuation and the speed of sound 
(Stiffness=0.67xBUA+0.28xSOS-420). SOS and BUA are influenced by the bone tissue, 
reflecting its density, architecture and elasticity, which may be useful in evaluation of fracture 
risk. The T-value is equal to the standard deviation from the mean value (Stiffness) in healthy 
young adults of the same gender and the Z-value is equal to the standard deviation from the 
mean value in age matched controls.  
3.3.7 DUAL ENERGY X-RAY ABSORPTIOMETRY 
Measurements with DXA (Hologic ZDR-4500A) BMD of the spine (lumbar vertebrae L1-
L4) and femoral neck were made in a subgroup of 34 participants (13 type 1 and 21 type 2). 
Standard operating procedures were followed for participant positioning. Scans were 
analyzed using Hologic software according to standard procedures. Characteristics in the 
subgroup which went through DXA measurements did not differ from the rest of the cohort. 
BMD is presented as percentage of the mean value (%BMD). The T-value is equal to the 
standard deviation (SD) from the mean value in young, healthy white males and females and 
the Z-value is equal to the SD from the mean value in age matched controls. 
3.3.8 RADIOIMMUNOASSAYS 
The IGF-system was assessed in a subgroup (n=30, 48%). IGF-I was determined in serum by 
RIA after separation of IGFs from IGFBPs by acid ethanol extraction and cryopercipitation. 
To minimize interference of remaining IGFBPs, des (1-3) IGF1 was used as radioligand. (60) 
The intra- and inter-assay CV values were 4% and 11% respectively. Serum levels of IGF-I 
are age dependent, decreasing with age, thus IGF-I values are expressed as SD scores 
compared to healthy adult subjects. IGFBP-1 in serum was determined by RIA using a 
polyclonal antibody and human IGFBP-1 as standard. (29) 
Serum IGFBP-4 was measured by an ELISA (DSL active IGFBP-4) assay according to the 
manufacturer’s directions. For all measurements, inter assay variability was less than 9% and 
intra assay variability was less than 7 %. (33)  
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IGFBP-5 was measured by radioimmunoassay for IGFBP-5 using recombinant human 
IGFBP-5 as the antigen, tracer, and standard. (34) 
The analysis of IGFBP-4 and -5 were made by Dr S Mohan, Loma Linda University, 
California. 
3.3.9 MEDICAL RECORDS AND REGISTERS 
Medical records regarding retinal photography were available after review of experienced 
retina ophthalmologists at the St Erik Hospital, Stockholm, Sweden. Retinopathy was 
classified as absent or present, ranging from mild non-proliferative retinopathy to 
proliferative retinopathy based on retina photographs. 
At follow up data were collected from the participant´s medical records. Incident fractures, 
amputations and development of Charcot foot deformations were based on registered ICD 
diagnosis. Incident fractures were verified by x-ray. Data on cause of death were obtained 
from The Swedish Health and Welfare Statistical Databases.  
3.3.10 STATISTICAL ANALYSES 
Statistical analysis was made in IBM SPSS Statistics. Pearson´s correlation test was used to 
measure linear dependence between variables. Independent sample T-test was used for 
comparison between groups. Logistic regression was used for categorical variables with 95% 
confidence intervals (CI). Friedman test, a non-parametric test, was used for testing the 
difference between several related samples. Significance level was set at p<0.05. Data are 
expressed as the mean ± SD for continuous variables or percentages for categorical variables. 
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4 RESULTS 
4.1 STUDY I 
4.1.1 INCIDENT HIP FRACTURE IN PATIENTS WITH TYPE 1 DIABETES 
MELLITUS 
This study included 24 605 subjects with T1DM (12 551 men and 12 054 women). Mean and 
median age at inclusion was 20,7 years. The cohort was followed for an average of 9.9 years 
(242 428 person years). During follow 121 incident hip fractures were recorded (70 among 
men, 51 among women). Anatomic site of fracture was the femoral neck in 64 (53%) and the 
per trochanteric area in 57 (47%) of the subjects. The mean age at diagnosis of first hip 
fracture was 43.1 years for women and 41.3 years for men.  
4.1.2 CUMULATIVE RISK OF HIP FRACTURE IN PATIENTS WITH TYPE 1 
DIABETES MELLITUS 
The cumulative risk of hip fracture among subjects with T1DM, stratified by sex, increased 
significantly after age 30 years. After age 40 years it increased more rapidly in men compared 
to in women.  
There was a significantly increased risk for hip fractures in both women and men with type 1 
DM (SHR=9.8, 95% CI 7.3-12.9 and SHR=7.6, 95% CI 5.9-9.6, respectively). Among 
women the excess risk increased with follow up duration (p < 0.02). The excess risks were 
evident in men across different durations of follow up but without a clear trend. The risk for 
hip fracture increased further when diabetic complications (neuropathy, nephropathy, 
retinopathy, cardiovascular) were present. There was no significant difference in incident hip 
fractures between women and men (univariate and multivariate analysis). Subjects with 
diabetic complications, particularly neuropathy and nephropathy, had generally higher 
relative risks for hip fracture. (Fig 1) 
 
Figure 1: Cumulative probability (per 1,000) of developing hip fracture before the age of 65 
years among type 1 diabetic patients, estimated by the Kaplan-Meier method. 
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4.2 STUDY II 
4.2.1 DIABETES 
To confirm the presence of diabetes in GK rats (female, 12 months old), intraperitoneal 
glucose tolerance test was performed. In control rats, the blood glucose levels peaked at 30 
min and subsequently returned to baseline. In GK rats the blood glucose levels were 
significantly higher, throughout the test duration. (Fig 2) 
4.2.2 RADIOGRAPHY 
Both the periosteal and endosteal diameters of the long bone diaphysis of humerus and tibia 
were significantly increased in GK rats compared to Wistar rats. However, the cortical 
thickness of humerus and tibia was not altered, whereas the cortical thickness index 
(periosteal/endosteal diameter) was significantly decreased in GK rats compared to Wistar 
rats.  
 
 
Figure 2: Blood glucose levels in the fasting state, 30 and 120 minutes after intra-peritoneal 
glucose injection (p<0.001).  
4.2.3 DUAL ENERGY X-RAY ABSORPTIOMETRY 
In GK rats the whole-body bone area was reduced compared to Wistar rats, indicating a 
smaller skeleton with a lower Bone Mineral Content leading to unchanged Bone Mineral 
Density (BMD). BMD in GK rats was significantly lower in the metaphysis of tibia and 
humerus, compared to controls, in sub-region analysis. In the diaphysis BMD was increased 
in tibia and decreased in humerus. The weight in GK rats did not significantly affect bone 
parameters, according to ANCOVA.  
4.2.4 THE IGF SYSTEM AND INSULIN 
Serum 
GK rats had significantly lower IGF-I levels in serum compared to Wistar rats, while IGFBP-
1 and IGFBP-4 levels were significantly higher. (Table 2) 
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Bone and ankle  
Local IGF-1 levels in diaphyseal cortical bone from tibia and femur was 38% lower in GK 
rats compared to Wistar rats (p < 0.05) but there was no difference in ankle and vertebrae. 
(Fig 3) 
  
Figure 3: Mean IGF-I concentrations in cortical bone, ankle joint and vertebrae according to 
RIA (p<0.05). 
4.3 STUDY III 
This study was performed in the same animals as in study II. 
4.3.1 DIABETES 
Higher blood glucose level in the fasting state, 30 and 60 min post-glucose tolerance test in 
GK rats compared to Wistar rats confirmed the presence of abnormal glucose tolerance in all 
GK rats. (Fig 2) 
4.3.2 NEUROPATHY 
Nerve function 
Nerve Conduction Velocity (NCV) in the sciatic nerve was reduced by 16% in GK rats 
compared to Wistar rats.  
Innervation  
In both GK rats and Wistar rats immunohistochemical analysis showed the presence of 
sensory (Substance P; SP, Calcitonin Gene Related Peptide; CGRP) and autonomic 
(Neuropeptide Y; NPY) nerve fibers in bone and joints, however sparse. In bone marrow 
sensory nerve fibers were only occasionally seen and mostly peri-vascular. Autonomic nerve 
fibers were frequently observed in bone marrow, both related to blood vessels and as free 
nerve terminals. Autonomic neuropeptides (NPY) was also observed in large multinucleated 
megakaryocytes and occasional mononuclear hematopoietic cells of the bone marrow. In 
cortical bone, autonomic nerves were seen in vascular canals, most frequently near the 
endosteal surface. (Fig 4) The occurrence of sensory neuropeptides was also analyzed in 
dorsal root ganglia and the spinal cord. Immunoreactivity for both sensory neuropeptides (SP 
and CGRP) was found in lamina I and II of the dorsal horn and the cell bodies of the dorsal 
root ganglia. No clear difference could be demonstrated between GK rats and Wistar rats. 
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Figure 4: Innervation: Immunohistochemistry showed the presence of both sensory (SP and 
CGRP) and autonomic (NPY) nerve fibers in bone and joints. White arrows = nerve fibers. 
Red arrows = NPY positive cells (megakaryocytes, mononuclear hematopoietic cells) 
A: Substance P, B: Calcitonin Gene Related Peptide, C and D: Neuropeptide Y 
Neuropeptide levels 
Radioimmunoassay (RIA) for sensory neuropeptides (SP and CGRP) in bone and joints did 
not demonstrate any significant difference between GK and Wistar rats. The levels of SP in 
periosteum and bone marrow were below detection limit and were excluded. In the spinal 
cord and dorsal root ganglia CGRP, but not SP, was significantly lower (-19% and -26% 
respectively) in GK rats. NPY concentrations in bone and joints were significantly decreased, 
notably, in cortical bone by -36%, in bone marrow by -66% and in ankle by -29%. 
4.4 STUDY IV 
4.4.1 STUDY SUBJECTS 
62 (27 T1DM, 35 T2DM) subjects were included in the study. Table 2a+c summarizes the 
participant´s characteristics at baseline and at follow up. Mean age at inclusion was 59 years 
(50±13.6 years in T1DM, 65±10.0 years in T2DM, p < 0.0001). There was no difference in 
mean age between women and men (data not shown). Mean DM duration was 20 years 
(28±13.6 years T1DM, 13±9.1 years T2DM, p < 0.0001) at inclusion. BMI was significantly 
lower in T1DM subjects compared to in T2DM subjects (24±3 and 27±6 respectively, p < 
0.007). There were no significant differences in blood pressure, number of insulin treated 
subjects, HbA1c and serum creatinine levels between T1DM an T2DM subjects. All 
participants had PNP, poor metabolic control and approximately 50% had nephropathy. The 
majority had retinopathy and increased blood pressure.  
A B 
 
 
C D 
 
Cortical bone 
    
Periosteum 
Cortical bone 
 
Cortical bone 
 
Bone marrow 
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Table 2a: Characteristics of the participants at baseline 
 
Characteristics of the participants at baseline. Mean ± SD are shown for continuous variables 
Characteristics   Type 1 DM (n=27)  Type 2 DM (n=35)  p-value
  Mean (SD)  (Mean (SD) 
Baseline  
Male (n, %)  n=13 (48)  n=21 (60)   
Age (years, (SD))  50 (13.6)  65(10.0)  0.0001 
Age range (years)  29-74  40-78 
Diab duration (years, SD) 28 (14)  13 (9)  0.0001 
Insulin treatment (n, %) 27 (100)  29 (83)  0.998 
BMI (kg/m2, SD)  24.15 (3.3)  27.49 (5.5)  0.007 
SBP (mmHg)  145 (18)  146 (17)  0.944 
HbA1c NGSP (%, SD) 8.7±1.6  8.3±1.4  0.296 
HbA1c (mmol/mol, SD) 74±19  69±17  0.288 
Creatinine (micromol/l) 89.4 (26)  85.8 (25)  0.594 
Microalbuminuria (n, %) 16 (59)  19 (54)  0.991 
Retinopathy (n, %)  25 (92)  25 (71)  0.051 
Peripheral neuropathy (n, %) 27 (100)  35 (100)  1 
Smoking (n, %)  12 (44)  20 (57)  0.323 
Physically inactive (n, %) 6 (22)  13 (37)  0.210 
Charcot at inclusion (n %) 7 (26)  8 (23)  0.780 
IGF-1 (SD)  -1.99 (1.29)  -0.20 (1.96)  0.006 
IGFBP-1 (microg/l)  104 (90.6)  39 (41.8)  0.012 
IGFBP-4 (microg/l)  825 (259.7)  897 (91.0)  0.485 
IGFBP-5 (microg/l)  635(86)  625 (91)  0.792 
SD: standard deviation 
BMI: Body Mass Index 
SBP: Systolic Blood Pressure 
DM: Diabetes Mellitus 
IGF-1: Insulin-like Growth Factor 1 
IGFBP: Insulin-like Growth Factor 1 Binding Protein 
Number of participants (%) are shown for categorical variables as YES/NO 
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Table 2b: Dual Energy X-ray Absorptiometry of the participants at baseline 
 
Dual energy X-ray absorptiometry, Trabecular Bone Score, Quantitative ultrasound 
Calcaneus 
Bone variables  Type 1 DM (n=27)  Type 2 DM (n=35)  p-value
  Mean (SD) 
QUS T-score (SD)  -1.77 (1.51)  -2.64 (1.36)  0,029 
QUS Z-score (SD)  -0.64 (1.32)  -0.89 (1.30)  0,486 
Stiffness  79.96 (16)  70.72 (15)  0.032 
BUA (dB/MHz)  110.65 (11)  106.39 (10)  0.14 
SOS (m/s)  1521.61 (33)  1499.71 (34)  0.022 
DXA spine T-score  -0.67 (1.3)  0.30 (1.8)  0.089 
DXA spine Z-score  -0.02 (1.2)  1.48 (1.6)  0,012 
DXA spine BMD (g/cm2) 1.00 (0.1)  1.14 (0.2)  0.067 
DXA femoral neck T-score (SD) -2.06 (0.88)  -1.82 (1.38)  0.567 
DXA femoral neck Z-score (SD) -1.06 (0.79)  0.002 (1.05)  0.006 
DXA femoral neck BMD (g/cm2) 0.718(0.08)  0.773 (0.19)  0.321 
Total Tissue fat (%)  31±9  30±7  0.813 
Lean body mass (%)  65±9  66±  0.660 
QUS: Quantitative ultrasound of calcaneus. BUA: Broad Band Attenuation. SOS: Speed of 
sound  
DXA: Dual Energy X-ray Absorptiometry. BMD: Bone Mineral Density  
T-score: SD compared to young adults 
Z-score: SD compared to age matched controls 
Total tissue fat %: whole body composition 
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Table 2c: Characteristics of the participants at follow up  
 
Characteristics of the participants at follow up. Mean ± SD are shown for continuous 
variables 
Characteristics   Type 1 DM (n=27)  Type 2 DM (n=35)  p-value
  Mean (SD)  (Mean (SD) 
Follow up time (years, SD) 11 (8)  10 (7)  0.278 
Mean HbA1c over time (%, SD) 8.8 (1.5)  8.2 (1.2)  0.072 
Any Fracture (n, %)  13 (48)  9 (26)  0.071 
Hip fracture (n (%)  3 (11)  2 (6)  0.447 
Foot fracture (n, %)   7 (26)  6 (17)  0.402 
Mean age at any fracture (years, SD) 54±14  66±9  0.023 
Diab dur. any fracture (years, SD)          39±12  16±10  0.0001 
Total cases of Charcot (n, %) 10 (37)  14 (40)  0.812 
New cases of Charcot (n, %) 3 (11)  6 (17) 
Amputation (n, %)  8 (30)  10 (28)  0.927 
Death (n, %)  15 (60)  29 (83)  0,020  
Mean age at time of death  70±10  75±9  0.077 
(years, SD) 
SD: standard deviation 
DM: Diabetes Mellitus 
Number of participants (%) are shown for categorical variables as YES/NO 
 
4.4.2 QUANTITATIVE ULTRASOUND AND DUAL ENERGY X-RAY 
ABSORPTIOMETRY (TABLE 2B) 
In a subgroup of 34 participants DXA spine and femoral neck mean T-score was -0.67±1.3 
and -2.06±0.88 SD respectively in T1DM subjects and 0.30±1.8 and -1.82±1.38 SD 
respectively in T2DM subjects. The difference between T1DM and T2DM subjects was only 
significant when corrected for age (p < 0.012 and p < 0.006 respectively, Z-score). The 
significant difference in T-score spine between women and men disappeared when corrected 
for age (Z-score). In femoral neck, there were no significant differences in neither T-score nor 
Z-score between women and men (p=0.098 and p=0.520 respectively).  
Mean T-score of QUS was significantly lower in T2DM subjects compared to in T1DM 
subjects (- 2.64±1.4 and – 1.77±1.5 respectively, p < 0.03) but the difference disappeared 
when corrected for age (Z-score). When corrected for age there was no significant difference 
between women and men.  
QUS T-score correlated significantly to T-score DXA spine and femoral neck (p < 0.004 and 
p < 0.0001 respectively). There was a significant correlation between QUS and DXA femoral 
neck even when corrected for age (Z-score, p < 0.01). There was a positive correlation 
between BMI and T-score DXA spine (r=0.412, p < 0.015) and femoral neck (r=0.441, p 
<0.009), but no significant correlation was seen between BMI and T-score QUS calcaneus.  
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Thus, at baseline, age corrected DXA values (spine and femoral neck) was significantly 
lower in T1DM subjects but did not significantly differ between women and men. Age 
corrected QUS values did not differ significantly between T1DM and T2DM subjects or 
between women and men. There was a significant correlation between DXA (spine and 
femoral neck) and QUS (calcaneus) values. 
4.4.3 FOLLOW UP EVENTS 
Fractures  
At follow up 22 of the participants (13 T1DM subjects, 9 T2DM subjects) had experienced 
one or multiple fractures (13 foot fractures, 3 lower limb fractures, 5 hip fractures, 2 vertebral 
fractures and 1 rib fracture). Fractures in the feet were most frequent. Median follow up time 
was 11 years in T1DM subjects and 8 years in T2DM subjects (range 1-20 years, 610 person 
years). Without adjustment for confounding factors there was no significant difference in 
fracture incidence between T1DM and T2DM subjects or between women and men. Mean 
age at the time of any fracture was 54±14 years in T1DM subjects and 66±9 years in T2DM 
subjects (p < 0.023) with no significant difference between women and men. T1DM subjects 
had significantly longer DM duration at the time of any fracture compared to T2DM subjects 
(39±12 years and 16±10 years respectively, p < 0.0001) with no significant difference 
between women and men. (Fig 2b. Table 1c) Neither smoking, HbA1c at inclusion, BMI, 
whole body tissue fat % nor gender was associated to increased incidence of any fracture. 
Logistic regression showed no increased incidence of any fracture in relation to measured T-
score and Z-score QUS calcaneus, Stiffness, BUA, SOS, T-score or Z-score DXA spine and 
femoral neck at inclusion. However, when exclusively considering fractures of foot and hip, 
age adjusted QUS calcaneus (Z-score) was associated to fracture incidence (p < 0.028). Age 
adjusted DXA spine (Z-score) was higher in T2DM subjects who sustained any fracture than 
in those who did not. CN was present in 9 subjects with foot fracture.  
Charcot Neuroarthropathy (CN) 
At follow up there were 9 new cases of CN (3 T1DM subjects, 6 T2DM subjects) identified 
in the participants medical records (ICD 10 code). In total 24 of included participants had 
CN. There was no association between CN development and DXA, TBS or QUS when 
corrected for age. There was a positive association between CN development and T-score 
DXA spine, but the difference disappeared when adjusted for age (Z-score). In subjects with 
CN, 9 had a foot fracture, 21 had a foot ulcer and 11 were amputated.  
Foot ulcer 
In 41 of the participants foot ulcer was present during the study period (14 T1DM, 27 
T2DM). In this group 10 subjects sustained a foot fracture, 21 subjects had CN and 17 were 
amputated. At follow up 36 (88%) of the subjects with foot ulcer had died.  
Mortality 
44 subjects had died at follow up. Mean age at time of death was 70±10 years in T1DM 
subjects and 75±9 years in T2DM subjects (p=0.077).  There was no difference in mean age 
at time of death between women and men. Low QUS values in calcaneus were associated to 
increased mortality (p < 0.001), even when corrected for age (p < 0.009, Z-score). Of the 
deceased subjects 36 had a history of foot ulcer, 19 CN, 15 amputations and 8 foot fracture. 
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Cardiovascular disease was the most frequent cause of death. Causes of death are listed in 
Table 3.   
 
Table 3: Causes of death 
 
Cause of death Number % of death cases 
Cerebrovascular event 11 25 
Cardiovascular event 14 31.8 
Malignancy  5 11.4 
Diabetes complications 9 20.4 
Septicemia  2 4.5 
Traffic casualty  1 2.3 
Intoxication  1 2.3 
Collum fracture  1 2.3 
 
 
Metabolic factors (BMI, HbA1c and the IGF-system) 
At baseline, there was a positive association between BMI and T-score DXA spine (r=0.412, 
p < 0.015) as well as femoral neck (r=0.441, p < 0.009), but not to T-score QUS calcaneus. 
BMI was not associated to incident fracture at follow up. However, T1DM subjects with any 
fracture had significantly lower BMI than T2DM subjects with any fracture. 
HbA1c at baseline did not correlate to DXA, QUS or TBS. At follow up there was a tendency 
to higher mean HbA1c over time in subjects with any fracture (p=0.081). 
IGF-I SD was significantly lower and IGFBP-1 significantly higher in T1DM compared to in 
T2DM subjects (p < 0.006 and p < 0.012 respectively) at baseline. There was no difference in 
IGFBP-4 or IGFBP-5 levels in between T1DM subjects and T2DM subjects. (Table 2a). IGF-
I SD was positively associated with DXA spine (r=0.459, p < 0.042) and femoral neck 
(r=0.437, p < 0.05) when adjusted for age, but not to QUS calcaneus. There was an inverse 
correlation between IGF-I SD and incidence of any fracture (p < 0.035), chiefly in T2DM 
patients. No association was seen between overall fracture incidence and IGFBP-4 or IGFBP-
5. However, when exclusively considering fractures of foot and hip, there was a significant 
inverse association with IGFBP-5 (p < 0.047). (Fig 6). HbA1c at baseline did not correlate 
with IGF-1, IGFBP-1, IGFBP-4 or IGFBP-5.  
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Figure 5: IGF-I SD (age corrected levels) in T1DM and T2DM patients with and without any  
                 fracture. 
  
Figure 6: Serum levels of IGFBP-5 in subjects with and without hip or foot fracture  
                 (p < 0.047). 
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5 DISCUSSION 
The results of this thesis are based on experimental animal studies, clinical studies and 
epidemiologic studies. The aim of our studies was to investigate the fracture incidence and 
possible predictors of fracture in patients with diabetes. 
 
5.1 FRACTURE INCIDENCE 
In the retrospective cohort study on T1DM patients we observed a distinctly increased hip 
fracture risk among men and women who had been hospitalized for T1DM as compared to 
the general population. Concurrent presence of diabetes complications such as neuropathy, 
nephropathy, retinopathy or cardiovascular disease indicated additional fracture risks ranging 
from 17- to 42-fold.  This is in accordance with subsequent reports. (73) The fact that only 
patients with T1DM diagnosed before the age of 30 years were included in study I may have 
resulted in inclusion of subjects with a longer duration of diabetes and thus more 
complications than in previous reports. (74) The high incidence of hip fracture before the age 
of 65 in study I, elucidate the necessity for development of methods for primary prevention in 
patients with T1DM.  
The association between fracture risk and neuropathy was further studied in the prospective, 
clinical study on T1DM and T2DM patients with PNP. We report a high incidence of any 
fracture, most prominent in the foot and hip, in this prospective clinical study. All participants 
had diabetes complications which presumably result in an overall higher fracture risk than in 
other studies. (75) The incidence of any fracture did not significantly differ between T1DM 
and T2DM patients, but tended to be higher in T1DM patients (p=0.071). The lack of a 
significant difference in fracture incidence between the T1DM and the T2DM patients in 
study IV could be due to a lack of statistical power. Regarding fractures of hip and foot there 
were no differences between T1DM and T2DM. Fracture incidence in study IV might be 
underestimated due to high mortality, high amputation frequency and undiagnosed fractures. 
In accordance with previous reports, the T1DM patients were younger, had longer DM 
duration and lower BMI than the T2DM patients in study IV. (76) Interestingly, in both study I 
and IV, the risk of fracture in men exceeded that in previous reports. In the general population 
fracture risk is higher in women compared to in men. (97) However, our results and available 
literature indicate that in the diabetes population men seems to be less protected from 
fractures. (98) Thus, the gender difference in fracture risk is different in diabetes patients 
compared to the general population. It is known that gender differences also differ regarding 
cardiovascular disease in diabetes patients as compared to the general population.  
The prospective clinical study is associated with several limitations. The sample size was not 
large enough to draw definitive conclusions concerning fracture risk. The material consisted 
of Caucasians only. Moreover, the participants were all included from the Foot clinic at the 
Karolinska University Hospital which is a tertiary hospital for diabetes and OP. The severity 
of disease in these patients is probably more pronounced than in the general diabetic 
population. We have not accounted for the frequency of falls or hypoglycemic events. Since 
the start of our study new bone turnover markers and methods of measuring bone quality 
have been discovered and have therefore not been considered in this report. Advantages in 
study IV are the long follow-up time, the clear distinction between T1DM and T2DM, 
inclusion of both men and women and that no participant was lost to follow-up.  The results 
indicate that PNP is a risk factor for bone disease and incident fractures in T1DM and T2DM 
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patients. It seems that these patients have regional bone disease since the incidence of 
fractures in the foot and hip were substantially higher than the risk for vertebral fractures. The 
vertebrae, metaphysis of long bones and calcaneus consists of trabecular bone.   
 
5.2 METABOLIC FACTORS 
5.2.1 Body mass index (BMI) 
High BMI is considered protective of fracture in non-diabetic individuals. Our results show 
that T1DM subjects with any fracture had lower BMI compared to those without fractures 
(study IV). In both the animal model of T2DM and in T2DM patients, body weight or BMI 
was not associated to BMD or fracture incidence (study II, III and IV). Thus, our results 
indicate that in T2DM subjects with complications, e.g. PNP, BMI does not seem to be 
sufficiently protective against fractures. 
 
5.2.2 HbA1c 
We did not find any significant association between HbA1c and bone parameters or fracture 
incidence. However, our data indicate that tight metabolic control is of importance 
considering the covariation between hip fracture and other DM complications. Furthermore, 
T1DM patients born before 1950, who presumably had T1DM a considerable time before the 
importance of metabolic control was identified, had extensively higher fracture risk (Study I).  
Hyperglycemia give rise to oxidative stress, hypoxia and the formation of AGEs. The 
formation of AGEs increases in the general population with age, but hyperglycemia 
accelerate this process in diabetic patients. AGE formation occurs in proteins in all tissues, 
including bone. The microcirculatory disturbances and microangiopathy seen in diabetes 
supposedly are associated to long term metabolic control and not to current HbA1c value. 
 
5.2.3 The IGF system 
The results of study II and IV indicate that the IGF system is disturbed, both systemically and 
locally, in DM. The animal model of T2DM showed reduced IGF-I activity with low IGF-I 
levels in both serum and cortical bone, high levels of IGFBP-1 and IGFBP-4 in serum and 
affected response of trabecular bone to local IGF-I. Abnormalities in the IGF system 
presumably, and to a certain extent, cause the reduction in BMD of trabecular bone in the 
metaphysis and the vertebrae of T2DM rats. The IGF-signaling pathway is crucial for bone 
acquisition and bone remodeling. (77) IGF-I has osteogenic properties and stimulates 
osteoblast differentiation and proliferation thereby playing a key role in maintenance of bone 
mass. The results from the prospective clinical cohort study (study IV) show that low serum 
IGF-I levels were associated with incidence of any fracture, confirming our previous study on 
rats with T2DM (GK-rat) and PNP reporting an association between decreased levels of IGF-
I (serum, bone) and regional osteopenia. This is consistent with previous reports of an 
association between decreased levels of IGF-I and fractures in patients with diabetes. (78) 
Normal ageing involves a decline in S-IGF-I. Our results showing low systemic and local 
IGF-I levels in T2DM rats with osteopathy and an association between low systemic IGF-I 
levels and fracture incidence in T1DM and T2DM patients, indicate that diabetes resemble 
premature ageing of bone tissue.  
In the animal model of T2DM serum levels of IGFBP-1 and IGFBP-4 were elevated. These 
proteins are expected to impair IGF-I action on bone and have a direct effect on osteoblasts 
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inhibiting bone formation. (33, 79) This indicates that the IGFBPs may affect bone metabolism. 
However, in the prospective clinical study, IGFBP-1 and -4 did not correlate with bone 
parameters or fracture incidence. Interestingly, low IGFBP-5 levels seemed to predict risk of 
fractures in the foot and hip. Our results agree with previous reports that IGFBP-5 potentiates 
IGF-I effects and functions as a growth factor by stimulating osteoblasts via an IGF-1 
independent mechanism. (34) 
Reports indicate that IGF-1 also affects the synthesis of nitric oxide (NO), which is involved 
in bone metabolism. (80) NO regulates bone metabolism by decreasing resorption, increasing 
formation and reducing oxidative stress. An association between cardiovascular disease and 
osteoporosis has previously been suggested and endothelial dysfunction may be an 
underlying mechanism. (81) The incidence of micro- and macrovascular disease was high in 
study IV suggesting a link between impaired bone metabolism, the IGF system and 
endothelial dysfunction. IGF-I decreases in patients with poorly controlled diabetes 
suggesting that optimal metabolic control may decrease the risk of future fractures.  
 
5.2.4 Peripheral neuropathy 
Our results consistently indicate an association between PNP and bone disease in diabetes. 
PNP is associated with impaired microcirculation, microangiopathy and subsequent hypoxia, 
contributing factors in diabetes bone disease.  In the prospective population-based cohort 
study of T1DM patients (Study I) the presence of PNP indicated excess risk of hip fracture 
that ranged from 17- to 42-fold. In the animal model of T2DM with osteopathy (Study III), 
NCV was reduced and we could demonstrate neuropeptidergic changes in bone and joints. In 
the prospective clinical study of T1DM and T2DM (Study IV), all participants had PNP and 
the fracture incidence was substantially high. There was also a high incidence of CN. In the 
general diabetes population CN is present in about 1% of diabetics (McInnes AD et al). It is 
known that diabetes and PNP are the most common precursors of CN. The pathogenesis of 
CN involves neurovascular disturbance due to pathological innervation of the blood vessels 
and repetitive micro-trauma of the bone and joints in the foot. Dysregulation of blood flow in 
bone due to autonomic neuropathy causes increased peripheral blood flow and bone 
resorption, osteopenia and local bone destruction. CN is characterized by presence of PNP, 
inflammation, rapid bone resorption and osteopathy. Sympathetic denervation causes 
increased bone perfusion and bone resorption linked to microvascular abnormalities. 
Microvascular changes in diabetes are enhanced by inflammation and may be associated to 
increased risk of incident fracture and CN. (92) PNP may be one factor causing the regional 
osteopathy seen in our studies. Presumably, progressive denervation leading to destruction of 
bone tissue in the foot and ankle increases the risk of fractures in the extremities, e.g. in the 
foot and hip, but not vertebral fractures.  
 
In rats with T2DM the neuropeptidergic changes pertained to the autonomic mediator NPY, 
whereas the sensory neuropeptides, SP and CGRP, were normal in the periphery. CGRP was 
decreased in dorsal root ganglia and spinal cord. This is in accordance with previous reports 
in which the onset of autonomic neuropathy precedes that of sensory dysfunction in patients 
with diabetes. (82-83) The GK rat presents a mild T2DM why, hypothetically, the decreased 
CGRP in dorsal root ganglia and spinal cord in the present study represents an early sign of 
sensory deficit eventually propagating to bone and joint in a more severe stage of the disease. 
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NPY is widely distributed in the central (CNS) and peripheral nervous system (PNS) and 
there are reports that NPY, centrally and peripherally, attenuates stress-induced bone loss. (84) 
Chronic stress is associated not only with psychiatric disease but also somatic disease, such as 
diabetes. In the periphery NPY is co-released with noradrenaline from noradrenergic neurons. 
Our results suggest that NPY has an anti-resorptive or pro-osteogenic effect on bone, 
consistent with previous reports. (45, 85-87) Given the suggested bone protective role of NPY 
during chronic stress, NPY deficiency in DM and PNP may be a contributing factor 
underlying the development of regional osteopenia.   
We suggest that the presence of PNP in DM patients should be considered as a risk factor for 
future fracture. 
 
5.2.5 Bone parameters 
In the animal model of T2DM DXA measurements showed significantly lower BMD in the 
metaphysis of both tibia and humerus in DM rats compared to controls. The BMC and BMD 
according to DXA were significantly reduced chiefly due to bone loss in vertebrae and 
metaphysis of long bones. Measurements with peripheral quantitative computed tomography 
have previously shown that the decrease in volumetric BMD almost exclusively affected 
trabecular bone (vertebrae, metaphysis) in the GK rat. (88) The metaphysis consists primarily 
of trabecular bone. The regional osteopenia seen in study II was associated with decreased 
levels of IGF-I in serum and in bone. In the prospective clinical study, IGF-I was associated 
with increased fracture risk in both T1DM and T2DM patients. Our results indicate that bone 
disease and fracture risk, at least to some degree, are caused by abnormalities in the IGF 
system. According to previous reports it seems like trabecular bone is more affected than 
cortical bone. (89) Our results indicate that trabecular bones in the extremities are more 
affected than in the spine, which may be due to PNP and dysfunctional vaso-regulation in the 
periphery.  
There was no significant difference in DXA T-scores at the femoral neck between T1DM and 
T2DM patients with PNP. DXA of spine and femoral neck did not predict future fracture in 
this cohort. Considering the small sample size this might be due to lack of statistical power.  
In study IV we performed QUS of the calcaneus in all patients. The parameters measured by 
QUS were low in both T1DM and T2DM patients. The gender difference disappeared when 
corrected for age. Low QUS of the calcaneus was associated with increased incidence of 
fracture in the foot and hip. Presumably the parameters of QUS calcaneus can reflect the bone 
structure of proximal femur and there are previous reports showing that QUS of calcaneus 
can predict risk of hip fracture (90) and that PNP is related to lower hip BMD and calcaneal 
QUS values. (91) Our results indicate that bone material properties, not captured by DXA, are 
altered in diabetes, particularly when PNP is present. Low QUS values, but not DXA, were 
associated to high fracture risk and mortality at follow up, in this population with multiple 
diabetes complications. Considering the hypothesis that AGEs in bone increase with age and 
long duration of diabetes, QUS may reflect the AGE content in bone and soft tissue of the 
foot, which is not captured by DXA.  
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6 CONCLUSIONS 
Both female and male subjects with T1DM are at increased risk for hip fracture, more 
common in those with neuropathy.  Subjects with T1DM and T2DM and PNP were at high 
risk for bone metabolic deterioration and consequent fractures, especially in the hip and foot. 
The co-occurrence with other diabetic complications suggests that tighter metabolic control 
might be of importance in the prevention of diabetic hip fracture. At follow up, there was also 
a tendency to association between HbA1c over time and incidence of any fracture.   
Female 12 months old GK rats with mild T2DM and neuropathy exhibited neuropeptidergic 
changes in the periphery with more pronounced autonomic neuropathy than sensory 
neuropathy. This is in accordance with observations in diabetic subjects, reporting the onset 
of sub-clinical autonomic neuropathy prior to development of sensory dysfunction. The 
results suggest that local neuropeptidergic deficit in diabetes may prove to be an important 
factor underlying the development of regional osteopathy. These GK rats exhibited regional 
osteopathy and disturbances in the IGF system. IGF-1 is an anabolic factor for bone and low 
levels have been shown to cause osteopenia. Both low systemic and local bone levels of IGF-
1 were related to local osteopenia. Accordingly, in the prospective clinical study of T1DM 
and T2DM low IGF-I SD serum levels were associated with the incidence of any fracture. 
When considering only fractures in foot and hip there was an inverse correlation between 
IGFBP-5 and fracture incidence. 
DXA spine was normal while DXA femoral neck and QUS calcaneus were low in T1DM and 
T2DM independent of gender, suggesting regional impairment in bone turnover in diabetes. 
Our results indicate that QUS calcaneus and not DXA might be used to screen for osteopenia 
and osteoporosis in subjects with diabetes and peripheral neuropathy and predict fractures in 
foot and hip. Hypothetically, QUS might reflect AGE accumulation in bone and soft tissue, 
not captured by DXA. 
In summary, currently used screening methods (DXA and FRAX) underestimate fracture risk 
in diabetes subjects. Our results indicate that the peripheral nervous system and the IGF 
system are involved in bone metabolism in diabetes and impairment in these systems can 
explain increased fracture risk. The risk of peripheral fractures seems to be increased more 
than axial fractures in diabetes patients with PNP.  This conforms to proposed regional 
osteopathy. Tight metabolic control and treatment normalizing  the IGF activity  already early 
after diabetes diagnosis and over time may have positive effect on the peripheral nervous 
system, AGE formation and resistance of bone to fracture. QUS of calcaneus, serum levels of 
IGF-I and IGFBP-5 could be complementary screening methods for fracture risk assessment 
in subjects with diabetes and PNP.   
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7 FUTURE PERSPECTIVES 
The incidence of DM, particularly T2DM, is increasing globally. Simultaneously, 
osteoporosis and increased fracture risk is frequent in many populations. In the ageing 
population these diseases generate a tremendous burden for the individual and the health care 
system. The results presented in this thesis indicate that both T1DM and T2DM are 
associated to increased fracture risk. The pathogenesis is multifactorial and complex. It is of 
importance to develop adequate screening methods to identify individuals at risk for future 
fracture and implement preventive measures. An increased understanding of the pathologic 
mechanisms leading to incident fracture is anticipated. A majority of T2DM patients are 
followed up in primary care. Evidence based screening tools and medical treatments are 
required to offer preventive and equal care for the broader population.  
Immigrant from the Middle East have higher prevalence and incidence of T2DM compared 
with native Swedes. (93) There are reports that low serum 25-hydroxyvitamin D levels 
increase risk of T2DM and increase fracture risk. (94-95)We have started a prospective cohort 
study on newly diagnosed T2DM subjects without DM complications. The participants are 
recruited from primary care units in the Stockholm area. In one group we include 100 patients 
with non-European origin and 100 controls matched for age, gender and origin. In the other 
group we include 100 native Swedish patients and 100 controls matched for age, gender and 
origin. The participants go through clinical examination (BMI, waist circumference, blood 
pressure, foot examination, eye examination) and a questionnaire regarding socioeconomic 
status, education, physical activity, diet, alcohol consumption, smoking habits, clothing 
(veiled) and heredity for T2DM and/or fracture. We will assess blood samples regarding 
metabolic control, vitamin D, vitamin D receptor, PTH, calcium, creatinine, GFR, 
adiponectin, sclerostin, osteoprotegrin, lipids and inflammation markers. The intention is to 
investigate AGE-levels, bone quality with microindentation method and assessment with 
QUS calcaneus. We will consider diabetic medication, frequency of hypoglycemia and risk of 
falls.  
 
In summary future prospective studies are required to determine the optimal management 
strategies for fracture prevention in diabetes. 
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